Laboratory of Cellular Immunology, Institute of Medical Biology of PAS, Lodz, Poland.
Proteon Pharmaceuticals S.A., Tylna 3A, 90-364, Lodz, Poland.
Sci Rep. 2022 May 16;12(1):8082. doi: 10.1038/s41598-022-12179-4.
Swab, RT-qPCR tests remain the gold standard of diagnostics of SARS-CoV-2 infections. These tests are costly and have limited throughput. We developed a 3-gene, seminested RT-qPCR test with SYBR green-based detection designed to be oversensitive rather than overspecific for high-throughput diagnostics of populations. This two-tier approach depends on decentralized self-collection of saliva samples, pooling, 1-tier testing with highly sensitive screening test and subsequent 2-tier testing of individual samples from positive pools with the IVD test. The screening test was able to detect five copies of the viral genome in 10 µl of isolated RNA with 50% probability and 18.8 copies with 95% probability and reached Ct values that were highly linearly RNA concentration-dependent. In the side-by-side comparison, the screening test attained slightly better results than the commercially available IVD-certified RT-qPCR diagnostic test DiaPlexQ (100% specificity and 89.8% sensitivity vs. 100% and 73.5%, respectively). Testing of 1475 individual clinical samples pooled in 374 pools of four revealed 0.8% false positive pools and no false negative pools. In weekly prophylactic testing of 113 people within 6 months, a two-tier testing approach enabled the detection of 18 infected individuals, including several asymptomatic individuals, with substantially lower cost than individual RT-PCR testing.
拭子、实时 RT-qPCR 检测仍然是 SARS-CoV-2 感染诊断的金标准。这些检测方法成本高,通量有限。我们开发了一种基于 SYBR Green 的三基因半巢式 RT-qPCR 检测方法,设计为高灵敏度而非高特异性,用于人群的高通量诊断。这种两阶段方法依赖于分散的唾液样本自我采集、汇集、用高灵敏度筛查试验进行一阶检测,然后对阳性池中的个体样本用 IVD 试验进行二阶检测。该筛查试验能够以 50%的概率在 10 μl 分离 RNA 中检测到五个拷贝的病毒基因组,以 95%的概率检测到 18.8 个拷贝,Ct 值高度依赖于 RNA 浓度的线性关系。在并行比较中,筛查试验的结果略优于市售的 IVD 认证 RT-qPCR 诊断试验 DiaPlexQ(特异性分别为 100%和 89.8%,敏感性分别为 100%和 73.5%)。对 1475 个个体临床样本进行了 374 个 4 人一组的汇集检测,发现 0.8%的假阳性汇集,没有假阴性汇集。在 6 个月内对 113 人进行每周预防性检测,两阶段检测方法能够检测到 18 名感染个体,包括数名无症状个体,成本远低于个体 RT-PCR 检测。